The ubiquitinproteasome system (UPS) is the main mechanism responsible for the intracellular degradation of misfolded or damaged proteins. Under inflammatory conditions, the immunoproteasome, an isoform of the proteasome, can be induced, enhancing the antigen-presenting function of the UPS. Furthermore, the immunoproteasome also serves nonimmune functions, such as maintaining protein homeostasis and regulating signalling pathways, and is involved in the pathophysiological processes of various cardiovascular diseases (CVDs). This review aims to provide a comprehensive summary of the current research on the involvement of the immunoproteasome in cardiovascular diseases, with the ultimate goal of identifying novel strategies for the treatment of these conditions.

In-stent restenosis (ISR) continues to be a significant problem after percutaneous coronary intervention (PCI), negatively affecting patient care. This review offers a thorough examination of current ISR diagnostic methods - which combine anatomical and functional assessments with cutting-edge technologies - with holistic recommendations for ISR management, from optimized prevention during PCI to effective treatment.

The immunoproteasome is linked to endothelial function and may act as a proangiogenic factor. This study explored its predictive value for coronary collateral circulation (CCC) in ST-elevation myocardial infarction (STEMI) patients. We enrolled 252 STEMI patients from April 2021 to April 2024. Plasma levels of LMP2, LMP7, and PSMB10 were measured using ELISA. ROC curves assessed predictive ability for good CCC. Univariate and multivariate logistic regression analyses identified predictors, and restricted cubic spline (RCS) analysis evaluated the dose-response relationship. Subgroup analysis was also conducted. Patients with good CCC had significantly higher plasma levels of immunoproteasome components. Among them, LMP7 showed the best predictive value (AUC = 0.732), with an optimal cut-off of 3.824 ng/mL. Multivariate logistic regression confirmed LMP7 ≥3.824 ng/mL as an independent predictor for good CCC [OR = 7.914 (4.127-15.174)]. RCS analysis showed a J-shaped association: the odds of good CCC increased notably when LMP7 exceeded 3.824 ng/mL. Subgroup analyses supported these findings. Higher plasma immunoproteasome levels, especially LMP7 ≥3.824 ng/mL, were independently associated with good CCC in STEMI patients, suggesting its potential role as a biomarker of collateral development.

Patients undergoing percutaneous coronary intervention (PCI) require long-term antiplatelet therapy to prevent thrombotic events. However, those at high bl

Objective: This study is designed to systematically assess the safety and efficacy profiles associated with varying procedural sequences of endovascular aortic repair (EVAR) and percutaneous coronary intervention (PCI) in clinical practice. Methods: We conducted a retrospective cohort analysis encompassing patients diagnosed with aortic aneurysm and concomitant coronary artery disease (CAD) who underwent EVAR at Beijing Anzhen Hospital, Capital Medical University, between January 2010 and December 2022, with planned staged (preoperative or postoperative) or simultaneous PCI. The cohort was stratified into three groups: PCI followed by EVAR, EVAR followed by PCI, and simultaneous EVAR and PCI. The primary endpoint was a composite of all-cause mortality, non-fatal myocardial infarction, cerebrovascular events, and aortic-related complications within 12 months post-intervention. Secondary endpoints included duration of hospital stay, total hospitalization costs, and incidence of in-hospital adverse events. Multivariate logistic regression analysis was employed to identify independent predictors of the primary endpoint. Results: The study cohort comprised 374 patients, with 209 (55.9%) undergoing PCI followed by EVAR, 133 (35.6%) receiving EVAR followed by PCI, and 32 (8.5%) undergoing simultaneous EVAR and PCI. Comparative analysis revealed no statistically significant differences in the incidence of in-hospital adverse events (p = 0.867) or the risk of primary endpoint events (p = 0.645) across the three treatment groups. Notably, the simultaneous treatment group demonstrated a significantly reduced total hospital stay (10.6 days) compared to the PCI followed by EVAR group (16.0 days) and the EVAR followed by PCI group (17.2 days) (p < 0.001), accompanied by lower hospitalization costs (p = 0.002). Conclusions: For patients with aortic aneurysm complicated by CAD requiring both EVAR and PCI, simultaneous intervention appears to be a safe and feasible therapeutic option. This approach significantly reduces hospital stay duration and associated costs without increasing the risk of in-hospital adverse events or compromising 12-month postoperative outcomes. However, this exploratory finding requires validation in large-scale randomized controlled trials.